Cardiol Therapeutics (CRDL) versus The Competition Financial Contrast

Cardiol Therapeutics (NASDAQ:CRDLGet Rating) is one of 255 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Cardiol Therapeutics to similar businesses based on the strength of its analyst recommendations, dividends, risk, institutional ownership, earnings, profitability and valuation.

Analyst Recommendations

This is a breakdown of current ratings for Cardiol Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiol Therapeutics 0 0 3 0 3.00
Cardiol Therapeutics Competitors 1657 5733 11373 210 2.53

Cardiol Therapeutics currently has a consensus price target of $6.67, indicating a potential upside of 484.80%. As a group, “Biological products, except diagnostic” companies have a potential upside of 116.81%. Given Cardiol Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than its competitors.

Insider and Institutional Ownership

16.6% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 53.2% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 16.8% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Cardiol Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cardiol Therapeutics $60,000.00 -$25.24 million -2.24
Cardiol Therapeutics Competitors $773.46 million $147.16 million -0.23

Cardiol Therapeutics’ competitors have higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Cardiol Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cardiol Therapeutics N/A -60.81% -53.72%
Cardiol Therapeutics Competitors -4,587.78% -67.40% -30.70%


Cardiol Therapeutics competitors beat Cardiol Therapeutics on 6 of the 11 factors compared.

About Cardiol Therapeutics (Get Rating)

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study; and LANCER design to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce major cardiovascular and respiratory events in patients hospitalized with COVID-19 that is in Phase II. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability for the treatment chronic heart failure. In addition, it develops proprietary nanotechnology to enable the distribution of water insoluble drugs within the blood circulation, enhance pharmacokinetics, and facilitate drug accumulation in the failing heart. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with's FREE daily email newsletter.